Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy.

ABSTRACT:

Objective

Anthracyclines are successfully used in cancer treatment, but their use is limited by their cardiotoxic side effects. Several risk factors for anthracycline-associated cardiomyopathy (AACM) are known, yet the occurrence of AACM in the absence of these known risk factors suggests that other factors must play a role. The purpose of this study was to evaluate whether a genetic predisposition for dilated cardiomyopathy (DCM) could be a potential risk factor for AACM.

Methods

A hospital-based registry of 162 DCM families and two hospital-based registries of patients with cancer treated with systemic cancer therapy (n>6000) were reviewed focusing on AACM. Selected patients with AACM/DCM families with possible AACM (n=21) were analysed for mutations in cardiomyopathy-asso

SUBMITTER: Wasielewski M 

PROVIDER: S-EPMC4195921 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature